FAQ
-- why everolimus: because it is an mTOR inhibitor like rapamycin and because mTOR inhibition is the most robust life extension technique so far (eg in mice it extends life even when started late in life) and because such low-risk-but-effective doses have been already established in healthy persons in various research studies (http://www.ncbi.nlm....ed/?term=rad001). The most well known is likely the recent 6-week use as a premedication to increase the response to the flu vaccine in elderlies (http://www.ncbi.nlm....pubmed/25540326)
-- is it allowed? It would be best to do it in a legal way. Since there has been discussions on the matter over the years without answer, I suggest to start and to be receptive to propositions to make it well recognized along the way.
-- how long would it last? what should we measure? We should typically report health (whenever we go to the doctor and report some health issue, have a sore throat, some flu, take some medicine...), during say one year before and then during the treatment. We should also indicate if we smoke/specific things that may make us healthy or not. The outcome would be a scoring system of health (eg counting 1 whenever we go to the doctor, take some medicine, etc.). Ideally we should report during say 5 years (epidemiologic studies of low-dose aspirin report positive results over 5 years)
-- would the data be public? Yes but people will be defined by a nickname that they don't use elsewhere so that their self-reporting is less biased by some potential avoidance to indicate bad health.
-- who would pay? the people who take the placebo-or-drug.
-- who would make the placebo-or-drug and send it? To be organized here.